AstraZeneca’s Dapagliflozin tablets get DCGI nod for chronic kidney disease
AstraZeneca Pharma India on Saturday mentioned it has received approval from the Medicines Controller Common of India (DCGI) for Dapagliflozin…
Change Your Business